Neuromodulation News

Vielight Commences Pivotal Clinical Trial for Alzheimer’s Disease based on Transcranial Photobiomodulation.

2019-05-24T13:12:05-04:00

Vielight Commences Pivotal Clinical Trial for Alzheimer’s Disease based on Transcranial Photobiomodulation.   Toronto, ON, May 22, 2019: Vielight Inc. of Toronto, a leader in brain photobiomodulation (PBM) technology, announces that the primary site for its pivotal clinical trial, St. Michael’s Hospital, in Toronto, has been activated. The trial will be a randomized, placebo-controlled study [...]